Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.90 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | ESRRG | P62508 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | TP53 | P04637 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | PGR | P06401 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | HTR6 | P50406 | 2/20 | 0.90 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | EGFR | P00533 | 1/20 | 0.90 |
| ▸ | GBA1 | P04062 | 1/20 | 0.90 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.90 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320201 | 1.00 | ESR1 (0.90) | ESR1ESR2MAPTESRRGMEN1 | |
| SCHEMBL2615530 | 1.00 | ESR1 (0.90) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL4084 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL17262111 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL119181 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| SCHEMBL29659348 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL4085 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL17262082 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTESRRGMEN1 | |
| Tamoxifen SCHEMBL5789295 | 0.93 | ESR1 (0.97) | ESR1ESR2MAPTESRRGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353132-B2 | Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer | XAVIER UNIVERSITY OF LOUISIANA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150080339-A1 | BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080339-A1 | BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER | ESR1, CYP4F2, DBF4 | ESR1 1/4885ESR2 61/4885MAPT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.